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Abstract
Background: There are a variety of treatment options for Bell’s palsy. Evidence from randomized controlled trials
indicates corticosteroids can be used as a proven therapy for Bell’s palsy. Acupuncture is one of the most
commonly used methods to treat Bell’s palsy in China. Recent studies suggest that staging treatment is more
suitable for Bell’s palsy, according to different path-stages of this disease. The aim of this study is to compare the
effects of prednisolone and staging acupuncture in the recovery of the affected facial nerve, and to verify whether
prednisolone in combination with staging acupuncture is more effective than prednisolone alone for Bell’s palsy in
a large number of patients.
Methods/Design: In this article, we report the design and protocol of a large sample multi-center randomized
controlled trial to treat Bell’s palsy with prednisolone and/or acupuncture. In total, 1200 patients aged 18 to 75
years within 72 h of onset of acute, unilateral, peripheral facial palsy will be assessed. There are six treatment
groups, with four treated according to different path-stages and two not. These patients are randomly assigned to
be in one of the following six treatment groups, i.e. 1) placebo prednisolone group, 2) prednisolone group, 3)
placebo prednisolone plus acute stage acupuncture group, 4) prednisolone plus acute stage acupuncture group, 5)
placebo prednisolone plus resting stage acupuncture group, 6) prednisolone plus resting stage acupuncture group.
The primary outcome is the time to complete recovery of facial function, assessed by Sunnybrook system and
House-Brackmann scale. The secondary outcomes include the incidence of ipsilateral pain in the early stage of
palsy (and the duration of this pain), the proportion of patients with severe pain, the occurrence of synkinesis,
facial spasm or contracture, and the severity of residual facial symptoms during the study period.
Discussion: The result of this trial will assess the efficacy of using prednisolone and staging acupuncture to treat
Bell’s palsy, and to determine a best combination therapy with prednisolone and acupuncture for treating Bell’s palsy.
Trial Registration: ClinicalTrials.gov: NCT01201642
Background
Bell’s palsy is an acute peripheral unilateral facial weak-
ness or paralysis with an as yet unknown cause. Bell’s
palsy accounts for almost three quarters of peripheral
facial palsies and the annual incidence is about 30
patients per 100 000. 71% of untreated patients with
Bell’s palsy will completely recover and 84% will have
complete or near normal recovery. The remainder will
have persistent moderate to severe weakness, facial con-
tracture, or synkinesis [1-3]. Because of its unclear
etiology, there has been longstanding controversy about
what treatment should be given, with potential alterna-
tives including corticosteroids, antiviral drugs, acupunc-
ture and physiotherapy. Inflammation of the facial nerve
is the most probable cause of Bell’s palsy. Therefore cor-
ticosteroids are commonly used as treatment of Bell’s
palsy. A recent study shows significant short-term and
long-term positive treatment effects of prednisolone in
patients with Bell’s palsy [4].
Acupuncture is a safe therapy with a low risk of
adverse events in clinical practice [5]. It is one of the
most commonly used treatments for Bell’sp a l s yi n
China. Chinese traditional acupuncture is low cost and
very convenient to local people. Though only limited
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Bell’s palsy [6], several studies provide increasing evi-
dence for a beneficial effect of acupuncture as an
adjunctive treatment of Bell’s palsy [7-10]. Bell’sp a l s y
has different path-stages; it includes acute stage (1-7
days onset of disease), resting stage (8-20 days onset of
disease) and restoration stage (21-90 days onset of dis-
ease) [11-14]. However, convincing evidence for the effi-
cacy of staging acupuncture to treat Bell’sp a l s yi s
lacking because of previous poor study designs, small
sample sizes or unclear reporting treatment. It’sn o t
clear whether acupuncture is effective in different path-
stages.
Thus, in view of these data, we designed this rando-
mized controlled multicentre study of Bell’sp a l s y
patients, with the aim of comparing the effects of pre-
dnisolone and staging acupuncture in the recovery of
the affected facial nerve. We also hoped to verify
whether staging acupuncture along with prednisolone is
more effective than prednisolone alone in larger number
of patients, especially in terms of reducing their level of
incapacity and improving their quality of life.
Methods/Design
Overview
This is a multicentre, randomized, placebo-controlled
study (Figure 1). This study has been approved by the
ethical committees of Xijing hospital and is registered
with ClinicalTrials.gov database (reference no.
NCT01201642). The study will be conducted according
to the Declaration of Helsinki.
Patients and enrolment
A power analysis is undertaken to calculate before con-
ducting this trial: a = 0.05 and power = 80%. According
to the previous literature, 70% of patients recover com-
pletely without treatment (placebo) compared with 80%
of patients treated with prednisolone, acupuncture, or
both. This difference of 10% is regarded as a clinically
significant improvement. Therefore, the sample size in
this trial can be estimated initially according to PASS
software. Each group needs at least 172 patients (assum-
ing a 15% dropout rate), 1200 patients in six groups will
be enrolled in the study.
Baseline assessments before the start of treatment
include neurological examination, grading of facial func-
tion, measurement of ipsilateral pain, documentation of
concurrent medication. Patients with acute, unilateral,
peripheral facial palsy, who are referred from neurology,
internal medicine or emergency departments, or who
seek care directly, are screened by physicians in 16 pub-
lic county hospitals and Xijing hospital in Shaanxi pro-
vince. There is at least one experienced neurology
physician, who is responsible for implementing the
study, with a special interest in facial palsy in each hos-
pital. A written consent form will be obtained from each
patient and retained by the investigators.
Inclusion criteria
Patients with Bell’ s palsy meeting the following inclu-
sion criteria are enrolled in the study: involvement of
unilateral facial nerve paralysis only, aged between 18
and 75 years old, period of onset of facial paralysis
within 72 h.
Exclusion criteria
Patients with any of the following are excluded: preg-
nancy, breastfeeding, being a woman of child bearing
age who is unwilling to use contraceptives during the
medication period, other neurological diseases, diabetes,
badly controlled hypertension, current or history of ser-
ious heart disease, history of renal or hepatic disease,
gastric or duodenal ulcer, history of glaucoma, acute oti-
tis or history of ipsilateral chronic otitis, history of
tuberculosis, history of immunodeficiency syndromes,
recent head injury, psychiatric disease, or any other con-
dition that is at risk of being influenced by the study
Recruitment  of patients
Informed consent
Baseline data collection 
Random assignment to group 
placebo
prednisolone 
group
(n=200)
prednisolone 
group 
(n=200)
placebo 
prednisolone 
plus         
acute stages 
acupuncture 
group
(n=200)
prednisolone 
plus         
acute stages 
acupuncture 
group
(n=200)
placebo 
prednisolone 
plus         
resting stages 
acupuncture 
group
(n=200)
prednisolone 
plus         
resting stages 
acupuncture 
group
(n=200)
Treatment period 20-35 days and 6 month follow-up
Data collection and trail outcome assessment 
Figure 1 Flow chart of the trial, describing the selection,
randomization and follow-up process.
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the study.
Randomization
Patients are to be randomly assigned to one of six treat-
ment groups. A computer-generated allocation sequence
(in permuted blocks with a block size of 12) will be cre-
ated by an operator who is not directly involved with
the study. Once created, the allocation sequence will be
kept in a secure locked drawer making it inaccessible to
all study personnel. Allocation concealment will be
achieved using sequentially numbered sealed envelopes
which are opaque when held to the light. When a
patient is enrolled in the study, an independent
researcher will be contacted and asked to give the next
numbered envelope to the physician who will make up
the medications to be used in the study. The indepen-
dent researcher will record the patient’s details and the
number of the envelope assigned to that patient. This
procedure ensures that the randomization is not influ-
enced by the researchers taking part in this study.
Interventions
Patients will be randomized to one of six treatment
arms: placebo prednisolone, prednisolone, placebo pre-
dnisolone plus acupuncture (acute stage), prednisolone
plus acupuncture (acute stage), placebo prednisolone
plus acupuncture (resting stage), or prednisolone plus
acupuncture (resting stage) within 72 h after onset of
Bell’s palsy.
Drug treatment: Prednisolone as 5 mg tablets will be
given within 72 h after onset of Bell’s palsy as a single dose
of 40 mg daily for 5 days; the dose will then be reduced by
10 mg per 5 day, with a total treatment time of 20 days.
Acupuncture therapy: On the basis of previous studies,
the acupuncture points used will be Dicang (ST4), Jiache
(ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-
HN5), Quanliao (SI18) and Yifeng (TE17) on the
affected side, and Hegu (LI4) bilaterally. A qualified acu-
puncturist will give the acupuncture in every center. For
acute stage acupuncture, shallow puncturing will be
used at facial acupoints and routine puncturing will be
used at other acupoints within 72 h after onset of Bell’s
palsy. Yifeng (TE17), Hegu (LI4) will be punctured 0.5-
1.0 cun, the others will be punctured 0.1-0.3 cun. For
resting stage acupuncture, penetrative needling will be
used from Dicang (ST4) to Jiache (ST6) and from
Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and rou-
tine puncturing will be used at other acupoints 7 d after
enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm)
will be used with moderate stimulation to get an acu-
puncture sensation, and the needles will be retained for
30 minutes, once a day, five times a week, for a total
period of four weeks. The locations of those points are
defined in 1993 by the World Health Organization
(WHO), Regional Office for the Western Pacific [15].
Outcomes
In order to reduce outcome assessment bias, the investi-
gators should be given specific training for facial grad-
ing, and both the Sunnybrook and House-Brackmann
scales will be used.
Primary outcome
The primary outcome measurement in this study is the
recovery of facial function before randomization and 7
d a y s ,1 7d a y s ,1m o n t h ,2m o n t h s ,3m o n t h s ,a n d6
months after randomization. Facial function will be
assessed at all visits with two grading systems (The Sun-
nybrook system and The House-Brackmann scale). If
recovery is complete (Sunnybrook scale score of 100
points) at 2 or 3 months, the next follow-up grading
will be at 6 months.
Secondary Outcome
Pain around the ear, in the face, or in the neck will be
registered on a visual analogue scale that ranges from 0
to 10 points, where 0 is no pain and 10 very severe
pain. Occurrence of facial spasm or contracture and
synkinesia in the different treatment arms at any time
will be observed and recorded.
Statistics
The study will be performed using intention to treat. In
this analysis, all randomized patients will receive at least
one therapy, but patients who did not start treatment
will be excluded (modified intention-to-treat analysis).
The last-observation-carried-forward method will be
used for the modified intention-to-treat analysis. The
missing data points will be imputed in the post-baseline
follow-up visits from the last observation available for
each patient. An interaction test was done to show the
synergistic effect of the combination of prednisolone
and acupuncture. Categorical variables will be compared
by using Fisher’s exact test. Cox proportional hazards
models will be used to estimate the hazard ratio (HR) of
recovery, including 95% CI. These will be compared
between groups by using t-tes t ,a n dM a n n - W h i t n e y ,o r
Chi-squared tests as appropriate. All statistical assess-
ments are two-sided, and a P value < 0.05 is considered
statistically significant.
Discussion
Bell’s palsy is a common disease. Recent evidence from
large randomized controlled trials indicates that corti-
costeroids are associated with a reduced risk of un-satis-
factory recovery in Bell’s palsy. Acupuncture, a therapy
of Chinese traditional medicine, has been recognized as
an alternative treatment method for many diseases. Its
effectiveness for Bell’s palsy has been shown by a few
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intervention time for acupuncture has been uncertain to
date. Many studies testified the effectiveness of staging
acupuncture by comparing results with non-staging acu-
puncture [14-18]. Although some research results
showed that there were differences between staging acu-
puncture and non-staging acupuncture to treat Bell’s
palsy, these trials had some methodological defects. For
instance, four clinical controlled trials illustrated that
the therapeutic effect of acupuncture treatment at differ-
ent path-stages was better than that of routine acupunc-
ture treatment for treating facial paralysis [16-19].
Randomization method was not used in these trials, and
the sample size was smaller than 80 clinical cases in two
studies [16,17], the biggest one being less than 130 clini-
cal cases [18,19]. In addition, the side effects during acu-
puncture treatment and the follow-up tests were not
reported in any of these trials. The design of the control
group was illogical as well [20]. So which method is the
best treatment at different path-stages for Bell’sp a l s y
needs to be investigated. Staging acupuncture, when
administered with corticosteroids, may also be asso-
ciated with additional benefits. In summary, the purpose
of this trial is to provide evidence of the effectiveness of
staging acupuncture to treat Bell’s palsy, and to find out
the best approach for treating this disease.
We expect to complete recruitment by December
2011 and anticipate that the results from this study will
have implications for health care resourcing and will
facilitate improvements in the treatment of people with
Bell’s palsy. The results of this study will also allow us
to determine, for the very first time, if a prednisolone
intervention alone is as effective at facilitating facial
nerve recovery as an intervention involving both predni-
solone and staging acupuncture. These results may have
important implications for the design of sustainable
cost-effective health services for people with Bell’s palsy.
Central randomization is used in our trial, which is a
strict, complete randomization, and it ensures adequate
concealment. During the whole trial, the patients are
not aware of which group they are to be assigned to,
but they do know they will receive acupuncture treat-
ment at different path-stages. Additionally, this trial is a
multicenter randomized controlled study, with six
months’ follow up, containing a large number of
patients. Up to now, our trial is one of the largest ran-
domized controlled trials addressing the effectiveness of
prednisolone in combination with staging acupuncture
treatment for Bell’s palsy.
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